Bausch Health Cos (NYSE:BHC) Price Target Lowered to $9.00 at Royal Bank Of Canada

Bausch Health Cos (NYSE:BHC) had its price target cut by Royal Bank Of Canada from $10.00 to $9.00 in a research note released on Monday morning,Benzinga reports. They currently have a sector perform rating on the stock.

BHC has been the topic of a number of other reports. Weiss Ratings cut shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Barclays cut their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Finally, Truist Financial upped their target price on Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research report on Wednesday, January 7th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $8.00.

Bausch Health Cos Stock Performance

Shares of BHC opened at $5.58 on Monday. Bausch Health Cos has a 1 year low of $4.41 and a 1 year high of $8.69. The firm has a fifty day moving average of $5.52 and a 200-day moving average of $6.20. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.47. The company has a market cap of $2.08 billion, a price-to-earnings ratio of 13.27 and a beta of 0.40.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 18th. The company reported $1.08 earnings per share for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.71 billion. As a group, equities analysts anticipate that Bausch Health Cos will post 4.15 earnings per share for the current year.

Institutional Investors Weigh In On Bausch Health Cos

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Paulson & CO. Inc. lifted its holdings in Bausch Health Cos by 3.5% in the 4th quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock valued at $509,128,000 after acquiring an additional 2,500,000 shares during the last quarter. Goldentree Asset Management LP lifted its holdings in Bausch Health Cos by 1.7% in the 3rd quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock valued at $224,409,000 after acquiring an additional 578,542 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Bausch Health Cos by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock valued at $78,808,000 after acquiring an additional 470,968 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Bausch Health Cos by 65.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock valued at $35,748,000 after acquiring an additional 2,038,813 shares during the last quarter. Finally, Norges Bank acquired a new stake in Bausch Health Cos in the 4th quarter valued at about $25,592,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.